(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.03%) $0.927
(0.21%) $10.86
(0.07%) $0.793
(-0.34%) $92.26
Live Chart Being Loaded With Signals
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome...
Stats | |
---|---|
Today's Volume | 238 548 |
Average Volume | 692 047 |
Market Cap | 45.64M |
EPS | SEK0 ( 2024-02-22 ) |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | 9.03 |
ATR14 | SEK0.00400 (1.11%) |
Lipigon Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lipigon Pharmaceuticals Financials
Annual | 2023 |
Revenue: | SEK16.41M |
Gross Profit: | SEK-12.58M (-76.66 %) |
EPS: | SEK-0.190 |
Q4 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-6 000.00 (0.00 %) |
EPS: | SEK-0.0882 |
Q3 | 2023 |
Revenue: | SEK357 000 |
Gross Profit: | SEK-5.40M (-1 513.45 %) |
EPS: | SEK-0.0295 |
Q2 | 2023 |
Revenue: | SEK16.05M |
Gross Profit: | SEK7.09M (44.15 %) |
EPS: | SEK0.110 |
Financial Reports:
No articles found.
Lipigon Pharmaceuticals
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators